Navigation Links
Hospira Announces FDA Approval of Topotecan Injection
Date:2/3/2011

LAKE FOREST, Ill., Feb. 3, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United States. The medication is a generic version of Hycamtin®, which had 2010 U.S. sales of more than $140 million. Hospira's topotecan is indicated for treatment of small cell lung cancer (SCLC) sensitive disease after failure of first-line chemotherapy.  

The solution formulation of topotecan, with a concentration of 4 mg/4 ml, is designed to improve caregiver convenience and safety, and Hospira expects to launch the product by the end of February.

"Hospira's solution version of topotecan expands our portfolio of value-added generics," said Thomas Moore, president, U.S., Hospira. "We're excited to offer the medical community access to a lower-cost, more convenient version of this key oncolytic."

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage™ drug delivery system and iSecure™ prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at www.hospira.com.

Private Securities Litigation Reform Act of 1995 -- A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the growth opportunities for generic specialty injectable products. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
2. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
3. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
4. Hospira to Present at Credit Suisse 18th Annual Healthcare Conference Nov. 11
5. Hospira Names Daphne E. Jones Chief Information Officer
6. Hospira Reports Third-Quarter 2009 Results
7. Hospira Supports Disaster Relief Efforts in Haiti With Products and Cash Grants
8. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
9. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
10. Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings
11. Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2017)... Md. , May 3, 2017  Kalorama ... growth of nine percent next year and this ... organ and hematopoietic stem cell (HSCT) or bone ... donor. Molecular testing technologies are well-suited for this task. ... market research publisher Kalorama Information. The various PCR-based ...
(Date:5/2/2017)... WASHINGTON and NEW YORK ... 2017 As the leading distributor of market ... with European Med Tech Reimbursement Consulting AB ... Med Tech Reimbursement Consulting AB,s proprietary market analyses through ... business professionals around the world easy access to complete ...
(Date:5/2/2017)... PASO ROBLES, Calif. , May 2, 2017  Bayer ... have received grants from Healthy Hives 2020, a $1 million ... in the U.S. by the end of 2020. ... Dr. Olav Rueppell , University of North Carolina at ... currently available honey bees; Dr. Edmund ...
Breaking Medicine Technology:
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Axiad ... organizations, today announced CIO Applications magazine has named the company a “Top 25 ... use of the Cloud to help organizations simply and proactively address potential cybersecurity threats ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the ... sectors, today announced the winners of its 3rd Annual ELITE Awards. The ELITE ... people in the healthcare industry today. , Out of more than 500 submissions, ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms Viability of ... Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom Price to ... ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May 21, 2017 ...
(Date:5/23/2017)... ... 23, 2017 , ... The National Council on Strength and ... the organization’s Certified Strength Coach credential has earned accreditation from the National Commission ... the competency of qualified candidates for jobs in the Strength and Conditioning profession. ...
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery of ... Sadati, is pleased to announce a new treatment option called Vivace Microneedling. This ... face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines ...
Breaking Medicine News(10 mins):